X4 PharmaceuticalsXFOR
About: X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Employees: 143
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
1,138% more call options, than puts
Call options by funds: $495K | Put options by funds: $40K
8.97% less ownership
Funds ownership: 56.78% [Q1] → 47.8% (-8.97%) [Q2]
48% less funds holding
Funds holding: 94 [Q1] → 49 (-45) [Q2]
78% less capital invested
Capital invested by funds: $23.6M [Q1] → $5.26M (-$18.3M) [Q2]
81% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 53
97% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 38
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Swayampakula Ramakanth | 12%downside $3.50 | Buy Maintained | 13 Aug 2025 |
Financial journalist opinion
Based on 3 articles about XFOR published over the past 30 days









